Search research articles
Contact Us
Filters
Showing results (41-50 of 89) with videos related to
Page
of 9
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology
|
April 6, 2004
PDGF C is a selective alpha platelet-derived growth factor receptor agonist that is highly expressed in platelet alpha granules and vascular smooth muscle
Li Fang, Yibing Yan, Laszlo G Komuves, et al.
British Journal of Cancer
|
August 17, 2019
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM
Karl D Lewis, James Larkin, Antoni Ribas, et al.
Investigational New Drugs
|
August 2, 2020
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
Geoffrey I Shapiro, Patricia LoRusso, Daniel C Cho, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2022
Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAF<sup>V600</sup> wild-type melanoma progressing on prior anti-programmed death-1 therapy
Shahneen Sandhu, Victoria Atkinson, Maria González Cao, et al.
General Psychiatry
|
January 26, 2024
Effects of a periodic intermittent theta burst stimulation in Alzheimer's disease
Xingqi Wu, Yibing Yan, Panpan Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2014
High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing
Richard Bourgon, Shan Lu, Yibing Yan, et al.
The Lancet. Oncology
|
February 26, 2018
Adjuvant vemurafenib in resected, BRAF<sup>V600</sup> mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Michele Maio, Karl Lewis, Lev Demidov, et al.
Alzheimer'S Research & Therapy
|
May 29, 2026
EEG biomarkers can predict early-stage Alzheimer's disease and correlate with intracerebral pathology: a multimodal machine learning study
Zhi Geng, Wenqian Song, Chen Gao, et al.
Genes & Cancer
|
July 24, 2014
Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition
Kyle A Edgar, Lisa Crocker, Eric Cheng, et al.
JCO Precision Oncology
|
February 9, 2022
Effects of Molecular Heterogeneity on Survival of Patients With <i>BRAF</i><sup>V600</sup>-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study
Matthew J Wongchenko, Antoni Ribas, Paolo A Ascierto, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 89) with videos related to
Sort By:
Page
of 9
Arteriosclerosis, Thrombosis, and Vascular Biology
|
April 6, 2004
PDGF C is a selective alpha platelet-derived growth factor receptor agonist that is highly expressed in platelet alpha granules and vascular smooth muscle
Li Fang, Yibing Yan, Laszlo G Komuves, et al.
British Journal of Cancer
|
August 17, 2019
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM
Karl D Lewis, James Larkin, Antoni Ribas, et al.
Investigational New Drugs
|
August 2, 2020
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
Geoffrey I Shapiro, Patricia LoRusso, Daniel C Cho, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2022
Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAF<sup>V600</sup> wild-type melanoma progressing on prior anti-programmed death-1 therapy
Shahneen Sandhu, Victoria Atkinson, Maria González Cao, et al.
General Psychiatry
|
January 26, 2024
Effects of a periodic intermittent theta burst stimulation in Alzheimer's disease
Xingqi Wu, Yibing Yan, Panpan Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2014
High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing
Richard Bourgon, Shan Lu, Yibing Yan, et al.
The Lancet. Oncology
|
February 26, 2018
Adjuvant vemurafenib in resected, BRAF<sup>V600</sup> mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Michele Maio, Karl Lewis, Lev Demidov, et al.
Alzheimer'S Research & Therapy
|
May 29, 2026
EEG biomarkers can predict early-stage Alzheimer's disease and correlate with intracerebral pathology: a multimodal machine learning study
Zhi Geng, Wenqian Song, Chen Gao, et al.
Genes & Cancer
|
July 24, 2014
Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition
Kyle A Edgar, Lisa Crocker, Eric Cheng, et al.
JCO Precision Oncology
|
February 9, 2022
Effects of Molecular Heterogeneity on Survival of Patients With <i>BRAF</i><sup>V600</sup>-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study
Matthew J Wongchenko, Antoni Ribas, Paolo A Ascierto, et al.
Page
of 9